Multiple Sclerosis Clinical Trial
Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy
Summary
The purpose of this study is to explore host genetic mutations which may render individual subjects more susceptible (or resistant) to developing Progressive Multifocal Leukoencephalopathy (PML). Samples will also be collected to determine Deoxyribonucleic Acid (DNA) sequence of JC Virus (JCV). Analysis of the JC Virus (JCV) genome may provide information about viral genotypes that may be associated with higher pathogenicity, and help to identify individuals who may be at higher risk of developing Progressive Multifocal Leukoencephalopathy (PML) due to chronic infection with a more pathogenic variant of JC Virus (JCV).
Full Description
Deoxyribonucleic acid (DNA) will be analyzed from natalizumab-treated subjects who develop Progressive Multifocal Leukoencephalopathy (PML). The genetic analysis of the subjects will directly seek mutations that could identify subjects at risk.
Eligibility Criteria
Key Inclusion Criteria:
Subjects who have confirmed PML while on treatment with Natalizumab
NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 10 Locations for this study
Cullman Alabama, 35058, United States
Aurora Colorado, 80045, United States
Chicago Illinois, 60612, United States
Indianapolis Indiana, 46260, United States
Hastings Nebraska, 68901, United States
Omaha Nebraska, 68105, United States
New York New York, 10003, United States
Rochester New York, 14642, United States
Cincinnati Ohio, 45208, United States
Bend Oregon, 97701, United States
Wuerzburg , , Germany
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.